First pediatric experience of SL-401, a CD123-targeted therapy, in patients with blastic plasmacytoid dendritic cell neoplasm: report of three cases

BACKGROUND: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a highly aggressive hematological malignancy with extremely poor outcome. The median overall survival for adult patients is 9–13 months. Pediatric patients are exceedingly rare with an unclear clinical course. Currently, no standard...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Weili, Liu, Huaying, Kim, Young, Karras, Nicole, Pawlowska, Anna, Toomey, Debbie, Kyono, Wade, Gaynon, Paul, Rosenthal, Joseph, Stein, Anthony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5932872/
https://www.ncbi.nlm.nih.gov/pubmed/29720227
http://dx.doi.org/10.1186/s13045-018-0604-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5932872/
https://www.ncbi.nlm.nih.gov/pubmed/29720227
http://dx.doi.org/10.1186/s13045-018-0604-6

Ejemplares similares